Cryptosporidium parvum Subverts Antimicrobial Activity of CRAMP by Reducing Its Expression in Neonatal Mice

William Guesdon1, Tiffany Pezier1, Sandrine Menard2

  • 1INRAE, Université de Tours, ISP, F-37380 Nouzilly, France.

Microorganisms
|October 29, 2020
PubMed

Insights

Cryptosporidium parvum infection reduces Cathelicidin Related Antimicrobial Peptide (CRAMP) expression in neonates. Exogenous CRAMP administration effectively reduced parasite burden, suggesting its therapeutic potential.

Area of Science:

  • Immunology
  • Parasitology
  • Microbiology

Background:

  • Cryptosporidium parvum causes diarrhea in vulnerable populations.
  • Antimicrobial peptides (AMPs) are crucial for innate immunity against C. parvum.
  • Cathelicidin Related Antimicrobial Peptide (CRAMP) is a key AMP in neonates.

Purpose of the Study:

  • To investigate the role of CRAMP in neonatal cryptosporidiosis.
  • To determine if C. parvum infection affects CRAMP expression.
  • To evaluate CRAMP as a potential therapeutic agent.

Main Methods:

  • Assessed CRAMP sensitivity to C. parvum sporozoites.
  • Measured intestinal CRAMP expression during infection.
  • Depleted CRAMP in neonates and assessed infection severity.
  • Administered exogenous CRAMP to infected neonates.

Main Results:

  • C. parvum sporozoites are sensitive to CRAMP's antimicrobial activity.
  • Intestinal CRAMP expression was significantly reduced during infection.
  • CRAMP depletion did not worsen infection, likely due to rapid downregulation.
  • Exogenous CRAMP administration reduced parasite burden in neonates.

Conclusions:

  • C. parvum actively downregulates CRAMP to evade the host immune response.
  • Exogenous cathelicidin supplementation represents a promising therapeutic strategy for cryptosporidiosis.

Related Concept Videos